Literature DB >> 11340301

Long-term ammonium chloride or sodium bicarbonate treatment in two models of polycystic kidney disease.

V E Torres1, B D Cowley, M G Branden, I Yoshida, V H Gattone.   

Abstract

Administration of ammonium chloride aggravates, while short-term administration of sodium or potassium bicarbonate lessens the development of polycystic kidney disease in Han:SPRD rats. We have conducted studies to determine whether the protection afforded by the administration of sodium bicarbonate is sustained and prevents development of uremia during chronic administration and whether the effects of the administration of ammonium chloride and sodium bicarbonate are also observed in a different model of polycystic kidney disease, the CD1-pcy/pcy mouse. We found that chronic administration of 200 mM sodium bicarbonate to Han:SPRD rats inhibited cystic enlargement and prevented the subsequent development of interstitial inflammation, chronic fibrosis, and uremia. We also found that, while the administration of ammonium chloride has similar effects in Han:SPRD rats and CD1-pcy/pcy mice, the administration of sodium bicarbonate is only protective in the Han:SPRD rats. This probably reflects differences in these models (predominately involvement of proximal tubules in Han:SPRD rats and of collecting ducts and distal tubules in pcy/pcy mice) and the different location and nature of the renal metabolic responses to the administration of acid or alkaline load. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11340301     DOI: 10.1159/000052609

Source DB:  PubMed          Journal:  Exp Nephrol        ISSN: 1018-7782


  8 in total

1.  Luminal alkalinization attenuates proteinuria-induced oxidative damage in proximal tubular cells.

Authors:  Tomokazu Souma; Michiaki Abe; Takashi Moriguchi; Jun Takai; Noriko Yanagisawa-Miyazawa; Eisuke Shibata; Yasutoshi Akiyama; Takafumi Toyohara; Takehiro Suzuki; Masayuki Tanemoto; Takaaki Abe; Hiroshi Sato; Masayuki Yamamoto; Sadayoshi Ito
Journal:  J Am Soc Nephrol       Date:  2011-03-03       Impact factor: 10.121

2.  Low Serum Bicarbonate and CKD Progression in Children.

Authors:  Denver D Brown; Jennifer Roem; Derek K Ng; Kimberly J Reidy; Juhi Kumar; Matthew K Abramowitz; Robert H Mak; Susan L Furth; George J Schwartz; Bradley A Warady; Frederick J Kaskel; Michal L Melamed
Journal:  Clin J Am Soc Nephrol       Date:  2020-05-28       Impact factor: 8.237

3.  Bicarbonate supplementation slows progression of CKD and improves nutritional status.

Authors:  Ione de Brito-Ashurst; Mira Varagunam; Martin J Raftery; Muhammad M Yaqoob
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

Review 4.  Consequences and therapy of the metabolic acidosis of chronic kidney disease.

Authors:  Jeffrey A Kraut; Nicolaos E Madias
Journal:  Pediatr Nephrol       Date:  2010-06-05       Impact factor: 3.714

Review 5.  Acidosis: progression of chronic kidney disease and quality of life.

Authors:  Ione de-Brito Ashurst; Emma O'Lone; Tarun Kaushik; Kieran McCafferty; Muhammad M Yaqoob
Journal:  Pediatr Nephrol       Date:  2014-08-02       Impact factor: 3.714

Review 6.  Recent advances in understanding the pathogenesis of polycystic kidney disease: therapeutic implications.

Authors:  Benjamin D Cowley
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Serum bicarbonate levels and the progression of kidney disease: a cohort study.

Authors:  Samir N Shah; Matthew Abramowitz; Thomas H Hostetter; Michal L Melamed
Journal:  Am J Kidney Dis       Date:  2009-04-25       Impact factor: 8.860

8.  Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.

Authors:  Lawrence J Appel; Jackson T Wright; Tom Greene; John W Kusek; Julia B Lewis; Xuelei Wang; Michael S Lipkowitz; Keith C Norris; George L Bakris; Mahboob Rahman; Gabriel Contreras; Stephen G Rostand; Joel D Kopple; Francis B Gabbai; Gerald I Schulman; Jennifer J Gassman; Jeanne Charleston; Lawrence Y Agodoa
Journal:  Arch Intern Med       Date:  2008-04-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.